Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy
| Autor: | Zhan Quan Li, Tsung O. Cheng, Yuan Zhe Jin, Li Liu, Wei Wei Zhang, Lin Yang Zhao, Ru Ming Guan, Shu Bin Qiao |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Percutaneous Heart disease business.industry medicine.medical_treatment Cardiomyopathy Hemodynamics medicine.disease Ablation Single Center Surgery Muscle hypertrophy Internal medicine medicine Cardiology Ventricular outflow tract Cardiology and Cardiovascular Medicine business |
| Zdroj: | International Journal of Cardiology. 93:197-202 |
| ISSN: | 0167-5273 |
| Popis: | Background : Percutaneous transluminal septal myocardial ablation (PTSMA) has been introduced as an alternative treatment for hypertrophic obstructive cardiomyopathy (HOCM). We report on the acute, short- and long-term results of our experiences in 119 patients from a single center in China. Methods and results : PTSMA was performed in 119 patients with symptomatic HOCM (mean age 35.4±14.8 years, male 80, female 39). All patients had echocardiography performed prior to the procedure, 2-week post-PTSMA, and 6-month post-PTSMA, and 65 patients had echocardiography repeated at 2-year follow-up. The average left ventricular outflow tract (LVOT) gradient was 67.3±7.8 mm Hg before the procedure, and 15.9±6.8 mm Hg after the procedure ( p p p Conclusions : PTSMA is a promising non-surgical procedure for symptomatic patients with HOCM because of its low risk and its significant hemodynamic, echocardiographic and clinical improvement. The significant therapeutic remodeling period was up to 6 months rather than 2 years following the procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect